Statins and renin-angiotensin system inhibitor combination treatment to prevent cardiovascular disease

Circulation Journal

Volumn 78, Issue 2, 2014, Pages 281-287

  Lee, Hae Young ^a   Sakuma, Ichiro ^f   Ihm, Sang Hyun ^b   Goh, Choong Won ^c   Koh, Kwang Kon ^d,e  

^a Seoul National University College of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Inje University College of Medicine   (South Korea)

^d Gachon University   (South Korea)

^e Gachon Cardiovascular Research Institute   (South Korea)

^f Hokko Memorial Clinic   (Japan)

Author keywords

Cardiovascular disease; Hypercholesterolemia; Hypertension; Renin angiotensin system inhibitors; Statins

Indexed keywords

ADIPONECTIN; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; CARVEDILOL; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; LISINOPRIL; NEBIVOLOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PRAVASTATIN; RAMIPRIL; RENIN ANGIOTENSIN SYSTEM INHIBITOR; RENIN INHIBITOR; SIMVASTATIN; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; GLUCOSE HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOKALEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ANIMAL; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR; UPREGULATION; VASCULAR ENDOTHELIUM;

ANIMALS; ATHEROSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; UP-REGULATION;

EID: 84892955353     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-1494     Document Type: Review

References (67)

1. Go AS, Bauman M, Coleman King SM, Fonarow GC, Lawrence W, Williams KA, et al. An effective approach to high blood pressure control: A Science Advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. J Am Coll Cardiol 2013 November 12, doi:10.1016/j.jacc.2013.11.007 [Epub ahead of print].
2. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013, November 12, doi:10.1161/01.cir.0000437738.63853.7a [E-pub ahead of print].
3. Lim S, Shin H, Song JH, Kwak SH, Kang SM, Won Yoon J, et al. Increasing prevalence of metabolic syndrome in Korea: The Korean National Health and Nutrition Examination Survey for 1998-2007. Diabetes Care 2011; 34: 1323-1328.
4. Jee SH, Jo J. Linkage of epidemiologic evidence with the clinical aspects of metabolic syndrome. Korean Circ J 2012; 42: 371-378.
5. Egan BM, Li J, Qanungo S, Wolfman TE. Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: National Health and Nutrition Examination Surveys 1988-2010. Circulation 2013; 128: 29-41.
6. Lee SR, Cha MJ, Kang DY, Oh KC, Shin DH, Lee HY. Increased prevalence of metabolic syndrome among hypertensive population: Ten years' trend of the korean national health and nutrition examination survey. Int J Cardiol 2013; 166: 633-639.
7. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-357.
8. Han SH, Quon MJ, Koh KK. Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction. Cur Opin Lipidol 2007; 18: 58-65.
9. Koh KK, Sakuma I, Quon MJ. Differential metabolic effects of distinct statins. Atherosclerosis 2011; 215: 1-8.
10. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004; 110: 3687-3692.
11. Koh KK, Quon MJ, Han SH, Ahn JY, Jin DK, Kim HS, et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 2005; 45: 1088-1093.
12. Joo SJ. Anti-inflammatory effects of statins beyond cholesterol lowering. Korean Circ J 2012; 42: 592-594.
13. Zavaroni I, Mazza S, Dall'Aglio E, Gasparini P, Passeri M, Reaven GM. Prevalence of hyperinsulinaemia in patients with high blood pressure. J Intern Med 1992; 231: 235-240.
14. Kaplan NM. Management of hypertension in patients with type 2 diabetes mellitus: Guidelines based on current evidence. Ann Intern Med 2001; 135: 1079-1083.
15. van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: A meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J 2012; 33: 2088-2097.
16. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-1357.
17. ALLHat Officers, Coordinators for the ALLHAT Collaborative Research Group The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
18. Wright JT Jr, Probstfield JL, Cushman WC, Pressel SL, Cutler JA, Davis BR, et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 2009; 169: 832-842.
19. Shafi T, Appel LJ, Miller ER 3rd, Klag MJ, Parekh RS. Changes in serum potassium mediate thiazide-induced diabetes. Hypertension 2008; 52: 1022-1029.
20. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis. Lancet 2007; 369: 201-207.
21. Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. Curr Med Res Opin 2010; 26: 615-629.
22. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial. JAMA 2004; 292: 2227-2236.
23. Celik T, Iyisoy A, Kursaklioglu H, Kardesoglu E, Kilic S, Turhan H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble p-selectin levels in hypertensive patients. J Hypertens 2006; 24: 591-596.
24. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Koh Y, et al. Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol 2010; 140: 73-81.
25. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40: 609-611.
26. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054-2057.
27. Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: A meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005; 46: 821-826.
28. Tuck ML, Bounoua F, Eslami P, Nyby MD, Eggena P, Corry DB. Insulin stimulates endogenous angiotensin ii production via a mitogen-activated protein kinase pathway in vascular smooth muscle cells. J Hypertens 2004; 22: 1779-1785.
29. Weiss D, Kools JJ, Taylor WR. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in ApoE-deficient mice. Circulation 2001; 103: 448-454.
30. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 1997; 95: 588-593.
31. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000; 20: 645-651.
32. Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS, et al. Pleiotropic effects of angiotensin ii receptor blocker in hypertensive patients. J Am Coll Cardiol 2003; 42: 905-910.
33. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
34. Koh KK. Effects of statins on vascular wall: Vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000; 47: 648-657.
35. Koh KK, Son JW, Ahn JY, Jin DK, Kim HS, Choi YM, et al. Vascular effects of diet and statin in hypercholesterolemic patients. Int J Cardiol 2004; 95: 185-191.
36. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin-sensitive dysregulated at1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131-2134.
37. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. JAMA 2011; 305: 2556-2564.
38. Koh KK, Lim S, Sakuma I, Quon MJ. Caveats to aggressive lowering of lipids by specific statins. Int J Cardiol 2012; 154: 97-101.
39. Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of l-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol 1999; 126: 1205-1213.
40. Kanda M, Satoh K, Ichihara K. Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol Pharmaceut Bull 2003; 26: 1681-1684.
41. Chamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3t3-l1 adipocytes. FEBS Lett 2001; 507: 357-361.
42. Koh KK, Quon MJ, Han SH, Lee Y, Ahn JY, Kim SJ, et al. Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care 2008; 31: 776-782.
43. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Park JB, et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 2009; 204: 483-490.
44. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 2010; 55: 1209-1216.
45. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-2207.
46. Koh KK, Quon MJ, Sakuma I, Han SH, Choi H, Lee K, et al. Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients. Int J Cardiol 2013; 166: 509-515.
47. Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man: A novel mechanism for insulin resistance. J Clin Invest 1990; 85: 1844-1852.
48. Vincent MA, Montagnani M, Quon MJ. Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium. Curr Diabetes Rep 2003; 3: 279-288.
49. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: Molecular and pathophysiological mechanisms. Circulation 2006; 113: 1888-1904.
50. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocrine Rev 2007; 28: 463-491.
51. Koh KK, Han SH, Oh PC, Shin EK, Quon MJ. Combination therapy for treatment or prevention of atherosclerosis: Focus on the lipid-RAAS interaction. Atherosclerosis 2010; 209: 307-313.
52. Lee BS, Choi JY, Kim JY, Han SH, Park JE. Simvastatin and losartan differentially and synergistically inhibit atherosclerosis in apolipoprotein E(-/-) mice. Korean Circ J 2012; 42: 543-550.
53. Lee HY, Youn SW, Cho HJ, Kwon YW, Lee SW, Kim SJ, et al. Foxo1 impairs whereas statin protects endothelial function in diabetes through reciprocal regulation of Kruppel-like factor 2. Cardiovasc Res 2013; 97: 143-152.
54. Nickenig G, Sachinidis A, Michaelsen F, Bohm M, Seewald S, Vetter H. Upregulation of vascular angiotensin ii receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997; 95: 473-478.
55. Oyama N, Yagita Y, Sasaki T, Omura-Matsuoka E, Terasaki Y, Sugiyama Y, et al. An angiotensin II type 1 receptor blocker can preserve endothelial function and attenuate brain ischemic damage in spontaneously hypertensive rats. J Neurosci Res 2010; 88: 2889-2898.
56. Li Z, Iwai M, Wu L, Liu HW, Chen R, Jinno T, et al. Fluvastatin enhances the inhibitory effects of a selective at1 receptor blocker, valsartan, on atherosclerosis. Hypertension 2004; 44: 758-763.
57. Han SH, Koh KK, Quon MJ, Lee Y, Shin EK. The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients. Atherosclerosis 2007; 190: 205-211.
58. Koh KK, Quon MJ, Han SH, Ahn JY, Lee Y, Shin EK. Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes. Atherosclerosis 2007; 194: 230-237.
59. Ceriello A, Assaloni R, Da Ros R, Maier A, Piconi L, Quagliaro L, et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 2005; 111: 2518-2524.
60. Koh KK, Lim S, Choi H, Lee Y, Han SH, Lee K, et al. Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia. Diabetes 2013; 62: 3547-3552.
61. Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome: Insights from therapeutic interventions. J Am Coll Cardiol 2005; 46: 1978-1985.
62. Han SH, Quon MJ, Kim JA, Koh KK. Adiponectin and cardiovascular disease: Response to therapeutic interventions. J Am Coll Cardiol 2007; 49: 531-538.
63. Koh KK, Park SM, Quon MJ. Leptin and cardiovascular disease: Response to therapeutic interventions. Circulation 2008; 117: 3238-3249.
64. Koh KK, Quon MJ. Targeting converging therapeutic pathways to overcome hypertension. Int J Cardiol 2009; 132: 297-299.
65. Lim S, Despres JP, Koh KK. Prevention of atherosclerosis in overweight/ obese patients: In need of novel multi-targeted approaches. Cir J 2011; 75: 1019-1027.
66. Lim S, Sakuma I, Quon MJ, Koh KK. Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality. Int J Cardiol 2013; 167: 1696-1702.
67. Lim S, Sakuma I, Quon MJ, Koh KK. Differential metabolic actions of specific statins: Clinical and therapeutic considerations. Antioxid Redox Signal 2013 September 24, doi:10.1089/ars.2013.5531 [Epub ahead of print].